Last month's worldwide cyberattack "NotPetya" forced Merck to halt drug production, reports Reuters.
Here are three things to know.
1. Merck said it was a victim of the attack in June, but did not disclose the manufacturing freeze at the time. The drugmaker is working to restore manufacturing operations and warned of temporary delivery delays for certain drug products.
"Full recovery from the cyberattack will take some time, but we are making steady progress," CEO Ken Frazier said on a recent conference call, according to Reuters.
2. Merck said it will be able to offer a continuous supply of its most popular drugs, including its cancer drug Keytruda and hepatitis C treatment Zepatier.
3. The company does not yet know the full impact of the operations disruption, but expects the shutdown to hurt annual profits.